X

Drug Profile

CO 003

Alternative Names: CO-003

Latest Information Update: 02 Jan 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CellOrigin
Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Macrophage replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

04 Dec 2023 Preclinical trials in Solid tumours in China (Parenteral) prior to December 2023 (CellOrigin pipeline, December 2023)
29 Mar 2022 CellOrigin has patent protection for CAR-iMac differentiation and engineering method in China and Australia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com